Company Overview - Pursuit Pharmaceutical Technology Co., Ltd. is located at 500 Guangdong Road, World Trade Building, 23rd Floor, Huangpu District, Shanghai, established on February 22, 2013, and listed on May 17, 2022 [1] - The company specializes in technology development, transfer, consulting, and services within the pharmaceutical sector, with 100% of its revenue derived from service activities [1] Financial Performance - For the period from January to September 2025, Pursuit achieved a revenue of 609 million yuan, representing a year-on-year growth of 2.59%, and a net profit attributable to shareholders of 87.38 million yuan, up 20.92% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 40.77 million yuan [3] Stock Performance - As of November 12, the stock price of Pursuit was 45.88 yuan per share, with a market capitalization of 3.625 billion yuan [1] - The stock has increased by 70.81% year-to-date, but has seen a decline of 6.04% over the last five trading days [1] Shareholder Information - As of October 31, the number of shareholders was 8,576, a decrease of 0.14% from the previous period, with an average of 8,782 circulating shares per shareholder, an increase of 0.14% [2] - Notable shareholders include Noan Pioneer Mixed A (320003) as the fifth largest shareholder with 3.29 million shares, and Tianhong Medical Health A (001558) as the eighth largest shareholder with 961,000 shares, which decreased by 467,700 shares from the previous period [3] Market Activity - On November 12, the stock experienced a trading volume of 57.36 million yuan, with a turnover rate of 1.63% [1] - The net inflow of main funds was 1.08 million yuan, with large orders accounting for 16.99% of purchases and 15.11% of sales [1] Industry Classification - Pursuit is classified under the Shenwan industry as part of the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [1] - The company is associated with various concept sectors including margin financing, buybacks, small-cap stocks, hepatitis treatment, and medical devices [1]
普蕊斯跌2.01%，成交额5735.91万元，主力资金净流入107.84万元